All In Biotech

Drug Trial Radar · NCT04306315

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Adjustable Brodalumab Dosage Regimen Compared With Standard Brodalumab Treatment for 52 Weeks in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

385

Actual

Start

Jul 21, 2022

Primary completion

Aug 25, 2025

Study completion Jan 5, 2026

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Mar 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg. The increased dosage regimen will be compared to the standard brodalumab treatment plus placebo.

Conditions

  • Psoriasis Vulgaris

Interventions

  • BrodalumabBiological

    Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Having at least 90% lower Psoriasis Area and Severity Index (PASI) score relative to baseline (PASI 90 response) at Week 40.Time frame: Week 40

Locations

81 sites in 11 countries. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Brussels, Belgium

  • LEO Pharma Investigational Site

    Ham-sur-Heure-Nalinnes, Belgium

  • LEO Pharma Investigational Site

    Leuven, Belgium

  • LEO Pharma Investigational Site

    Liège, Belgium

  • LEO Pharma Investigational Site

    Kutná Hora, Czechia

  • LEO Pharma Investigational Site

    Nový Jičín, Czechia

  • LEO Pharma Investigational Site

    Plzen-Bory, Czechia

  • LEO Pharma Investigational Site

    Saint-Priest-en-Jarez, France

  • LEO Pharma Investigational Site

    Toulouse, France

  • LEO Pharma Investigational Site

    Valence, France

  • LEO Pharma Investigational Site

    Amiens, Somme, France

  • LEO Pharma Investigational Site

    Bad Bentheim, Germany

  • LEO Pharma Investigational Site

    Bielefeld, Germany

  • LEO Pharma Investigational Site

    Hamburg, Germany

  • LEO Pharma Investigational Site

    Memmingen, Germany

  • LEO Pharma Investigational Site

    Münster, Germany

  • LEO Pharma Investigational Site

    Oldenburg, Germany

  • LEO Pharma Investigational Site

    Osnabrück, Germany

  • LEO Pharma Investigational Site

    Langenau, Baden-Wurttemberg, Germany

  • LEO Pharma Investigational Site

    Limburg an der Lahn, Hesse, Germany

  • LEO Pharma Investigational Site

    Wiesbaden, Hesse, Germany

  • LEO Pharma Investigational Site

    Lohne, Lower Saxony, Germany

  • LEO Pharma Investigational Site

    Mainz, Rhineland-Palatinate, Germany

  • LEO Pharma Investigational Site

    Kiel, Schleswig-Holstein, Germany

  • LEO Pharma Investigational Site

    Berlin, State of Berlin, Germany

  • LEO Pharma Investigational Site

    Athens, Greece

  • LEO Pharma Investigational Site

    Athens, Greece

  • LEO Pharma Investigational Site

    Piraeus, Greece

  • LEO Pharma Investigational Site

    Thessaloniki, Greece

  • LEO Pharma Investigational Site

    Thessaloniki, Greece

  • LEO Pharma Investigational Site

    Thessaloniki, Greece

  • LEO Pharma Investigational Site

    Heraklion, Crete, Greece

  • LEO Pharma Investigational Site

    Debrecen, Hungary

  • LEO Pharma Investigational Site

    Orosháza, Hungary

  • LEO Pharma Investigational Site

    Szolnok, Hungary

  • LEO Pharma Investigational Site

    Veszprém, Hungary

  • LEO Pharma Investigational Site

    Ancona, Italy

  • LEO Pharma Investigational Site

    Bologna, Italy

  • LEO Pharma Investigational Site

    Brescia, Italy

  • LEO Pharma Investigational Site

    Coppito, Italy

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.